ASH 2024 | Long-term outcomes of alloSCT for T-cell prolymphocytic leukemia
Olivier Tournilhac, MD, PhD, Clermont-Ferrand University Hospital, Clermont-Ferrand, France, comments on the long-term outcomes of allogeneic stem cell transplantation (alloSCT) for T-cell prolymphocytic leukemia (T-PLL), a rare hematological malignancy with dismal prognosis. Prof. Tournilhac reports the results of a study completed on behalf of the Chronic Malignancies Working Party (CMWP) of the European Society for Blood and Marrow Transplantation (EBMT), which highlighted that transplant outcomes in patients with T-PLL remain poor. This underscores the need to explore alternative alloSCT bridging approaches and conditioning regimens to improve survival outcomes for these patients. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
